Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses.
Antiviral Agents
/ chemistry
Common Cold
/ drug therapy
Coronavirus 229E, Human
/ drug effects
Coronavirus Infections
/ drug therapy
Coronavirus NL63, Human
/ drug effects
Coronavirus OC43, Human
/ drug effects
Cytidine
/ analogs & derivatives
Humans
Hydroxylamines
/ pharmacology
Molecular Docking Simulation
Protein Binding
/ drug effects
Pyrrolidines
/ pharmacology
RNA-Dependent RNA Polymerase
/ chemistry
Seasons
Sulfonic Acids
/ pharmacology
Virus Replication
/ drug effects
Drug repurposing
Molnupiravir
RdRp
Seasonal coronavirus
Journal
Virology
ISSN: 1096-0341
Titre abrégé: Virology
Pays: United States
ID NLM: 0110674
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
16
08
2021
revised:
29
09
2021
accepted:
29
09
2021
pubmed:
8
10
2021
medline:
16
11
2021
entrez:
7
10
2021
Statut:
ppublish
Résumé
Endemic seasonal coronaviruses cause morbidity and mortality in a subset of patients, but no specific treatment is available. Molnupiravir is a promising pipeline antiviral drug for treating SARS-CoV-2 infection potentially by targeting RNA-dependent RNA polymerase (RdRp). This study aims to evaluate the potential of repurposing molnupiravir for treating seasonal human coronavirus (HCoV) infections. Molecular docking revealed that the active form of molnupiravir, β-D-N
Identifiants
pubmed: 34619630
pii: S0042-6822(21)00200-2
doi: 10.1016/j.virol.2021.09.009
pmc: PMC8486977
pii:
doi:
Substances chimiques
Antiviral Agents
0
Hydroxylamines
0
Pyrrolidines
0
Sulfonic Acids
0
Cytidine
5CSZ8459RP
RNA-Dependent RNA Polymerase
EC 2.7.7.48
GC376
H1NMJ5XDG5
molnupiravir
YA84KI1VEW
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
33-38Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Nat Commun. 2020 Sep 4;11(1):4417
pubmed: 32887884
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
J Virol. 2018 Jan 17;92(3):
pubmed: 29167335
Lancet Microbe. 2020 Aug;1(4):e151
pubmed: 33521716
J Infect Dis. 2020 Jul 23;222(4):695-696
pubmed: 32497175
Proc Natl Acad Sci U S A. 2005 May 31;102(22):7988-93
pubmed: 15897467
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
Nature. 2021 Mar;591(7850):451-457
pubmed: 33561864
Nat Protoc. 2011 Jun;6(6):925-33
pubmed: 21637207
Nat Med. 2004 Apr;10(4):368-73
pubmed: 15034574
Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493
pubmed: 32246720
Antimicrob Agents Chemother. 2003 Jan;47(1):244-54
pubmed: 12499198
J Virol. 2019 Nov 26;93(24):
pubmed: 31578288
J Med Virol. 2021 Feb;93(2):1002-1007
pubmed: 32720706
Clin Infect Dis. 2021 Aug 2;73(3):554-555
pubmed: 32926168
Viruses. 2015 Dec 01;7(12):6233-40
pubmed: 26633464
Nat Microbiol. 2021 Jan;6(1):11-18
pubmed: 33273742
Sci Transl Med. 2019 Oct 23;11(515):
pubmed: 31645453